Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients With Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

NCT06724237 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.

NCT NCT06724237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06724237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients With Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lead sponsor
Eastern Cooperative Oncology Group
Phase
Phase 3
Overall status
Recruiting
Start date
June 18, 2025
Completion date
April 30, 2075
Enrollment
294 (estimated)
Sites
165

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, alk-negative, follicular helper t-cell lymphoma, follicular helper t-cell lymphoma, angioimmunoblastic-type, peripheral t-cell lymphoma, not otherwise specified